Reuters logo
in 6 months
BRIEF-Sorrento Therapeutics unit says key endpoints met in EU Pivotal Bioequivalence Clinical Study for ZTlido
January 9, 2017 / 5:28 PM / in 6 months

BRIEF-Sorrento Therapeutics unit says key endpoints met in EU Pivotal Bioequivalence Clinical Study for ZTlido

1 Min Read

Jan 9 (Reuters) - Sorrento Therapeutics Inc -

* Sorrento subsidiary, Scilex Pharmaceuticals, announces key endpoints met in the European Union Pivotal Bioequivalence Clinical Study for its lead product, ZTlido

* Sorrento Therapeutics Inc- Marketing Authorization Application is expected to be filed in mid-2017 for ZTlido Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below